Evaluation of the efficacy of TFPI2 as a novel ovarian tumor marker in real world

Abstract

Synopsis: Tissue Factor Pathway Inhibitor 2 (TFPI2) is a tumor marker demonstrating high specificity in distinguishing ovarian clear cell carcinoma from other types of ovarian tumors. In Japan, TFPI2 became a part of insurance coverage since April 2021. As fewer cases were presented after the insurance coverage, we investigated the usefulness of TFPI2 in the diagnosis of ovarian cancer. We studied 124 cases, including 67 (54.0%) benign tumors, 12 (9.7%) borderline tumors, and 45 (36.3%) malignancies. Comparing the benign tumors group with the combined borderline tumors and malignancies groups, the combined benign and borderline tumors groups and malignancies group, and the ovarian clear cell carcinoma group and the non-clear cell carcinoma group, both CA125 and TFPI2 showed significant differences, effectively distinguishing the groups. However, when comparing the ovarian clear cell carcinoma group with the ovarian endometrial cyst group, TFPI2 demonstrated a significant difference, while CA125 did not. These findings indicate that TFPI2 can be used alongside conventional tumor markers in real world as well.